PEB have just completed a long and exhaustive process having their products accepted by regulators and potential customers. If you change supply of one of the components of your product (if indeed there is another relevant MK-antibody supplier available) you have to get the product approved again by the regulators, if not also by the customers.
Why would they start the process again?
I think we can assume that CDY will continue to be the supplier to PEB.
poorinvestor
PacificEdge update, page-199
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| AN1 (ASX) Chart |
Day chart unavailable